ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2025
Apoptosis-inducing photodynamic therapy via dual-wavelength responsive ICG/Ce6 incorporated mesoporous silica nanoparticles in prostate cancer cells.
Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Current State of Research in the Field of Photosensitizers and Photoactivators for Photodynamic/Photothermal Cancer Therapy: A Review.International journal of molecular sciences · 2025Review
- Photodynamic Therapy Combined with Gemcitabine for Prostate Cancer Using Nanoprobe for in-vivo CEST Imaging.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Photodynamic therapy (PDT) destroys cancer cells by photoactivation of photosensitive agents with minimal side effects on healthy tissue. Due to its limitations, using nanoparticles is a promising strategy to increase the efficacy of PDT. Mesoporous silica nanoparticles (MSN) are advantageous candidates for delivering the photosensitizer with their biocompatibility, pore structure, and large surface area. In this study, a novel design of MSN is produced by incorporating indocyanine green (ICG) and chlorin e6 (Ce6) into its structure. A dual-laser system is set up with 655- and 808-nm diode lasers for the PDT applications on prostate cancer cells (PC3). After the applications, the action mechanism is investigated via cell viability, cell staining, mechanistic, and qRT-PCR analyses. 100 μg/ml of nanoparticle concentration shows the highest anticancer PDT activity with a rate of 75% decrease in cell viability and exhibits minimal side-effect on healthy cells. Besides the overexpression of the Caspase 3 gene, all mechanistic and staining analyses support the apoptotic cell death mechanism of PDT in the presence of this nanoparticle. This study shows that PDT mediated by the novel design of MSN is a promising treatment for lethal cancer types and will enlighten future studies.
Indexed as
Identifiers
40715791What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.